

( (S (NP-SBJ Par Pharmaceutical Inc.)
     (VP said
         (SBAR 0
               (S (NP-SBJ it)
                  (VP (VP named
                          (NP (NP its interim 
				  (NX (NX president) 
				      and 
				      (NX chief executive officer)))
                              ,
                              (NP Kenneth I. Sawyer)
                              ,)
                          (PP-CLR to
				  (NP those posts))
                          (ADVP-MNR permanently))
                      , 
		      and
                      (VP elected
                          (NP him)
                          (PP-CLR to
				  (NP the board)))))))
     .))
( (S (NP-SBJ Par)
     (ADVP also)
     (VP said
         (SBAR 0
               (S (NP-SBJ-1 it)
                  (VP was
                      (VP advised
                          (NP *-1)
                          (PP by
                              (NP-LGS (NP the U.S. attorney)
				      (PP for
					  (NP Maryland))))
                          (SBAR that
                                (S (NP-SBJ it)
                                   (VP is
                                       (NP-PRD (NP one)
                                               (PP of
                                                   (NP (NP a number)
                                                       (PP of
                                                           (NP (NP companies)
                                                               (VP being
                                                                   (VP investigated
								       (NP *) 
                                                                       (PP by
                                                                           (NP-LGS a federal grand jury))
                                                                       (PP-PRP for
									       (NP (NP alleged violations)
										   (PP of
										       (NP the federal Food , Drug and Cosmetic Act)))))))))))))))))))
     .))
( (S (NP-SBJ (NP Par)
             ,
             (NP (NP a generic-drug maker)
                 (SBAR (WHNP-2 that)
                       (S (NP-SBJ-1 *T*-2)
                          (VP has
                              (VP been
                                  (VP plagued
                                      (NP *-1)
                                      (PP by
                                          (NP-LGS management problems))))))))
             ,)
     (VP was
         (ADVP-TMP already)
         (NP-PRD (NP the subject)
                 (PP of
                     (NP (NP (NP a federal criminal inquiry)
                             (PP into
                                 (NP the drug-approval process)))
                         and
                         (NP a Food and Drug Administration investigation)))))
     .))
( (S (NP-SBJ A Par spokesman)
     (VP said
         (SBAR 0
               (S (NP-SBJ he)
                  (VP understood
                      (SBAR 0
                            (S (NP-SBJ (NP the criminal investigation)
                                       (PP-LOC in
					       (NP Maryland)))
                               (VP relates
                                   (PP-CLR to
					   (NP (NP matters)
					       (SBAR (WHNP-1 0)
						     (S (NP-SBJ Par)
							(VP disclosed
							    (NP *T*-1)
							    (PP-TMP in
								    (NP (NP July)
									,
									(SBAR (WHADVP-2 when)
									      (S (NP-SBJ Par)
										 (VP said
										     (SBAR 0
											   (S (NP-SBJ it)
											      (VP filed
												  (NP false drug information)
												  (PP-CLR with
													  (NP the FDA)))))
										     (ADVP-TMP *T*-2))))))))))))))))))
     .))
( (S (PP-TMP At
	     (NP the time))
     ,
     (NP-SBJ the company)
     (VP said
         (SBAR 0
               (S (NP-SBJ-1 it)
                  (VP (VP was
			  (VP recalling
			      (NP (NP one)
				  (PP of
				      (NP its drugs)))))
		      and
		      (VP had
			  (VP stopped
			      (S (NP-SBJ *-1)
				 (VP selling
				     (NP two others)))))))))
     .))
( (S (NP-SBJ The spokesman)
     (VP said
         (SBAR 0
               (S (NP-SBJ he)
                  (ADVP also)
                  (VP understood
                      (SBAR that
                            (S (NP-SBJ the inquiry)
                               (VP related
                                   (PP-CLR to
					   (NP (NP the existence)
					       (PP of
						   (NP an `` off-the-record '' production book)))))))))))
     .))
( (S (NP-SBJ The book)
     (VP noted
         (NP (NP changes)
	     (VP made
		 (NP *)
		 (PP-LOC at
			 (NP the manufacturing level)))
             (SBAR (WHNP-1 that)
                   (S (NP-SBJ-2 *T*-1)
                      (VP were n't
                          (VP disclosed
			      (NP *-2)
                              (PP-CLR to
				      (NP the FDA))))))))
     .))
( (S (NP-SBJ Par)
     (VP said
         (SBAR 0
               (S (NP-SBJ it)
                  (VP is
                      (VP cooperating
                          (PP-LOC-CLR in
				      (NP the investigation)))))))
     .))
( (S (ADVP Also)
     (NP-TMP yesterday)
     ,
     (NP-SBJ-1 (NP Ashok Patel)
               ,
               (NP (NP a former Par official)
                   (SBAR (WHNP-2 who)
                         (S (NP-SBJ-3 *T*-2)
                            (VP pleaded
                                (ADJP-PRD guilty
					  (PP to
					      (S-NOM (NP-SBJ *-3)
						     (VP providing
							 (NP an FDA employee)
							 (NP (NP an illegal gratuity)
							     (PP of
								 (NP $ 3,000 *U*)))))))))))
               ,)
     (VP was
         (VP sentenced
             (NP *-1)
             (PP by
                 (NP-LGS a federal judge))
	     (PP-LOC in
		     (NP Baltimore))
             (PP-CLR to
		     (NP (NP (NP one year)
			     (PP of
				 (NP community service)))
			 and
			 (NP a (ADJP (QP $ 150,000) *U*) fine)))))
     .))
( (S (NP-SBJ-1 Mr. Patel)
     (ADVP also)
     (VP was
         (VP placed
             (NP *-1)
             (PP-CLR on
		     (NP (NP three years ')
			 probation))))
     .))
( (S (NP-SBJ Mr. Patel)
     (VP resigned
         (PP as
             (NP (NP senior vice president)
                 (PP of
                     (NP Par))))
         (PP-TMP in
		 (NP April)))
     .))
( (S (PP-TMP In
	     (NP July))
     ,
     (NP-SBJ-1 (NP Par)
	       and
	       (NP a 60%-owned unit))
     (VP agreed
         (S (NP-SBJ *-1)
            (VP to
                (VP plead
                    (ADJP-PRD guilty)
                    (PP-LOC in
			    (NP that inquiry))
		    ,
		    (SBAR-ADV as
			      (SINV did
				    (NP-SBJ another former Par official)
				    (VP *?*)))))))
     .))
( (S (NP-SBJ-1 Mr. Sawyer)
     (VP began
         (S (NP-SBJ *-1)
            (VP running
                (NP the company)
                (PP on
                    (NP an interim basis))
                (PP-TMP in
			(NP late September)))))
     .))
( (S (NP-SBJ Par)
     (VP said
         (SBAR 0
               (S (NP-SBJ it)
                  (VP selected
                      (NP him)
                      (PP-CLR for
			      (NP (NP the posts)
				  (PP of
				      (NP (NP president)
					  and
					  (NP chief executive)))))
                      (PP on
                          (NP a permanent basis))
                      (PP-PRP because of
                              (NP (NP (NP his experience)
                                      (PP-LOC in
					      (NP the industry)))
                                  and
                                  (NP (NP his performance)
                                      (PP-LOC at
					      (NP Par)))))))))
     .))
( (S (NP-SBJ (NP Perry Levine)
             ,
             (NP chairman)
             ,)
     (VP said
         (SBAR 0
               (S (NP-SBJ Mr. Sawyer)
                  (VP had
                      (VP `` 
			  taken
                          (NP (NP significant steps)
			      ''
			      (SBAR (WHNP-1 0)
				    (S (NP-SBJ *T*-1)
				       (VP to
					   (VP restore
					       (NP (NP the company 's)
						   (NX (NX credibility)
						       and 
						       (NX (NX sense)
							   (PP of
							       (NP professionalism and integrity)))))))))))))))
     .))
